Articles Accepted

Erlotinib is actively expressed in tumor cells by blocking EGFR signaling and thereby control growth of tumor cells. Self-assembled mixed micelles as targeted therapy can accumulate drug in tumor cell. Pluronic F127 and TPGS were used to prepare micelles and evaluated. Box Behnken design was applied to optimize formulation. With optimum ratio invitro dissolution was performed and pharmacokinetic parameters were predicted. Optimization with Minitab software which revealed Design matrix and graphical presentation via contour plot. F1 to F15 batches showing the range of 42-133 nm size and 55-82% of entrapment. The issue of low drug entrapment into the micellar core would be overcome by using polymers in optimized concentration with 0.9% NaCl and 37ºC temperature. Critical micelles concentration was found to be 3× 10 -5 M. Drug release of optimized mixed micelles was found 84.91± 1.58 % in 72 hrs. In nutshell, self-assembled mixed micelles would be platform for targeting anticancer agents.